Open AccessThe efficacy of melatonin against radiotoxicity of iodine-131 and its response to treatment in hyperthyroid patients: a randomized controlled trial
Author(s) -
Soudabe Alidadi,
Ali Shabestani Monfared,
Mehrangiz Amiri,
Ebrahim Zabihi,
Ehsan Assadollahi,
Amir Gholami,
Zoleika Moazezi,
Zeinab Abedian
Publication year - 2022
Publication title -
nuclear medicine review
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.216
H-Index - 21
eISSN - 1644-4345
pISSN - 1506-9680
DOI - 10.5603/nmr.a2022.0007
Subject(s) - melatonin , medicine , placebo , micronucleus test , iodine , randomized controlled trial , micronucleus , gastroenterology , clinical trial , chemotherapy , toxicity , pathology , materials science , alternative medicine , metallurgy
Since melatonin is a non-toxic compound with proven radioprotective effects, we aimed to investigate its efficacy in an in-vivo setting in hyperthyroid patients who are treated with iodine-131. This double-blind placebo-controlled study was conducted on hyperthyroid patients referred to nuclear medicine centers in Babol, Iran. We excluded patients suffering from hypertension treated with warfarin, autoimmune diseases, genetic diseases, cancers, smokers, chemical wounded, radiology and radiotherapy workers, and those who were treated with chemotherapy agents. Patients were randomly assigned to receive a capsule containing 300 mg of melatonin powder or a placebo. Just before receiving iodine-131, blood samples were taken from individuals. All 52 female patients received 10 to 20 mCi iodine-131 for treating hyperthyroidism. A second blood sample was taken one hour after the administration of iodine-131.